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Clinical Significance 
 Major adverse outcomes of non-hemorrhagic stroke, death and major bleeding do not 
differ between asymptomatic and symptomatic presentations of atrial fibrillation. 
 Adverse outcomes in asymptomatic and symptomatic atrial fibrillation presentations 
are comparably reduced by oral anticoagulation.  
 Opportunistic screening in everyday practice to detect asymptomatic atrial fibrillation 
may be beneficial as it likely has the same prognosis as asymptomatic atrial 
fibrillation at presentation and likely responds similarly to oral anticoagulation. 
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ABSTRACT 
Background: Asymptomatic atrial fibrillation is often detected incidentally. Prognosis and 
optimal therapy for asymptomatic compared to symptomatic atrial fibrillation is uncertain.  
This study compares clinical characteristics, treatment, and 2-year outcomes of asymptomatic 
and symptomatic atrial fibrillation presentations. 
Methods: GARFIELD-AF is a global, prospective, observational study of newly diagnosed 
atrial fibrillation with ≥1 stroke risk factors (http://www.clinicaltrials.gov. Unique identifier: 
NCT01090362). Patients were characterized by atrial fibrillation-related symptoms at 
presentation and the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, 
stroke/transient ischemic attack, vascular disease, age 65-74 years, sex (CHA2DS2-VASc) 
score. Two-year follow-up recorded anticoagulation patterns (vitamin K antagonist [VKAs], 
direct oral anticoagulants [DOACs], parenteral therapy) and outcomes (stroke/systemic 
embolism, all-cause mortality, and bleeding). 
         
Results: At presentation, 52,032 eligible patients, 25.4% were asymptomatic, and 74.6% 
symptomatic. Asymptomatic patients were slightly older (72 vs. 70 years), more often male 
(64.2% vs. 52.9%), and more frequently initiated on anticoagulation ± antiplatelets (AP) 
(69.4% vs. 66.0%). No difference in events (adjusted hazard ratios, 95% CI) for non-
hemorrhagic stroke/systemic embolism (1.19, 0.97-1.45), all-cause mortality (1.06, 0.94-
1.20), or bleeding (1.02, 0.87-1.19) was observed. Anticoagulation was associated with 
comparable reduction in non-hemorrhagic stroke/systemic embolism (0.59, 0.43–0.82 vs. 
0.78, 0.65–0.93) and all-cause mortality (0.69, 0.59-0.81 vs. 0.77, 0.71-0.85) (asymptomatic 
vs symptomatic, respectively).  
Conclusions: Major outcomes do not differ between asymptomatic and symptomatic atrial 
fibrillation presentations and are comparably reduced by anticoagulation.  Opportunistic 
screening-detected asymptomatic atrial fibrillation likely has the same prognosis as 
asymptomatic atrial fibrillation at presentation, and likely responds similarly to 
anticoagulation thrombo-prophylaxis. 
Key words: Atrial fibrillation, asymptomatic, symptomatic, anticoagulation. 
 
Atrial fibrillation is the commonest sustained cardiac arrhythmia in adults and is associated 
with an elevated risk of ischemic stroke, heart failure, cognitive impairment, hospitalisations, 
and death 
1-4
. Many patients with atrial fibrillation present with recognizable symptoms or 
complications such as palpitations, stroke or heart failure, however, approximately one third 
of cases are diagnosed with no or non-specific symptoms (i.e. asymptomatic) 
5-11
. These 
patients are frequently detected during physical examinations for other conditions, routine 
preoperative assessments, health checks (including blood pressure or pulse examination), or 
more recently, when participating in atrial fibrillation surveillance programs 
12-15
.  
         
Opportunistic or systematic screening for asymptomatic atrial fibrillation could involve 
significant resource costs 
16,17
. This, however, could be justified if the patients identified were 
high-risk individuals eligible for initiation of an oral anticoagulant (OAC) 
18-23
, potentially 
preventing stroke or premature mortality. Cost–benefit balance is largely determined by 
actual risk of stroke or death in asymptomatic presentations whether detected incidentally 
24
 




Previous studies, which have been mostly retrospective in design, small scale, or have not 
been limited to asymptomatic patient presentation, have indicated that patients with “silent 
atrial fibrillation” have similar prognosis to those with symptomatic atrial fibrillation, 
showing comparable mortality, ischemic stroke, and bleeding 
6,28-30
.  Two studies have 





 compared to atrial fibrillation with typical symptoms. 
Whether OAC therapy, encompassing both Vitamin K antagonists (VKAs) and direct oral 
anticoagulants (DOAC) exerts comparable beneficial effects in asymptomatic and 
symptomatic atrial fibrillation patients remains uncertain, although pivotal randomized trials 




The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study 
was designed prospectively to investigate outcomes in a large cohort of patients with newly 
diagnosed atrial fibrillation. The aim of the present analysis was to compare clinical 
characteristics, patterns of treatment, and 2-year outcomes in GARFIELD-AF stratified by 
the presence of asymptomatic or symptomatic disease at baseline. 
  
         
METHODS 
GARFIELD-AF study design 
The design of GARFIELD-AF has been reported elsewhere 
33,34
. Eligible men and women 
(≥18 years) were diagnosed with non-valvular atrial fibrillation, according to standard local 
procedures, within 6 weeks prior to entry to the registry. All eligible patients required at least 
one additional risk factor for stroke, as judged by local investigators, to be considered eligible 
for inclusion. Between 2010 and 2016, five separate cohorts of patients were enrolled 
prospectively and consecutively in 35 countries. Study sites represent the different care 
settings in each participating country (office-based practice; hospital departments including 
neurology, cardiology, geriatrics, internal medicine, and emergency; anticoagulation clinics; 
and general practice). Independent ethics committee and hospital-based institutional review 
board approvals were obtained. A list of central ethics committees and regulatory authorities 
that provided approval can be found in online (e-Appendix 1).  The registry is conducted in 
accordance with the principles of the Declaration of Helsinki, local regulatory requirements, 
and International Conference on Harmonization–Good Pharmacoepidemiological and 
Clinical Practice guidelines. Written informed consent was obtained from all study 
participants, and their confidentiality and anonymity are maintained. 
Procedures and outcome measures 
Clincal characteristics documented at baseline included medical history, care setting, type of 
atrial fibrillation, date and method of diagnosis, symptoms, antithrombotic treatment, and 
cardiovascular drug prescriptions. In addition, data on components of the congestive heart 
failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack 
(TIA), vascular disease, age 65 to 74 years, sex category (CHA2DS2-VASc) and the 
hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, 
labile INR, elderly, drug/alcohol usage (HAS-BLED) risk stratification schemes were 
         
collected. Collection of follow-up data was performed every 4 months up to 2-years after 
enrolment. Data were captured by electronic case report forms (eCRFs). Submitted data were 
examined for completeness and accuracy by the coordinating center (Thrombosis Research 
Institute, London, UK); for quality control, 20% of eCRFs were automatically monitored 
against source documentation. Data used for the present analysis were extracted in November 
2018. 
Patients were considered symptomatic if they had at least one of the following clinical 
features documented at baseline: palpitations, shortness of breath, chest pain/discomfort, 
dizziness, tiredness, sweating, or fainting; those with signs such as irregular pulse and/or 
tachycardia but no symptoms were considered asymptomatic. 
Statistical analysis 
Baseline characteristics are presented for asymptomatic and symptomatic patients. 
Continuous variables are summarized as medians (1st and 3rd quartile) and categorical 
variables as absolute frequencies (percent). Event rates were estimated as the number of 
events per 100 person years. Only the first occurrence of each event/patient was considered. 
A multivariable Cox proportional hazard model was applied to estimate hazard ratios (HRs) 
for association between symptoms at diagnosis and outcomes. 
Propensity score methodology was adopted to allow for balanced comparison between 
treatment groups (i.e. OAC versus no OAC). To control for balance covariate differences an 
overlap weighting scheme was applied, which optimizes efficiency of comparisons by 
defining the population with the highest overlap in covariates between treatment groups. The 
underlying propensity score, calculated as the probability for receiving OAC, was obtained 
using a logistic regression model including a large range of demographic and clinical 
covariates (e-Table 1). Weights were subsequently applied to a Cox proportional hazards 
model to estimate OAC effects on selected clinical endpoints within each of the two groups. 
         
Treatment was defined as that initiated on enrollment, approximating "intention to treat." 
Patients with missing values were not removed from the study; single imputation was applied 






Of the 52,080 enrolled patients, 52,032 had complete follow-up information. Of these, 13,235 
patients (25.4%) were asymptomatic and 38,797 patients (74.6%) presented with symptoms 
(Figure 1).  Compared with the symptomatic group, asymptomatic patients were more likely 
male, older, and to have suffered prior stroke, but had a lower prevalence of heart failure, and 
vascular disease (Table 1). The two groups had similar median CHA2DS2-VASc and HAS-
BLED scores. Asymptomatic patients were more likely than symptomatic patients to be 
diagnosed in the office (43% vs 25%, P<0.001), and less likely to be diagnosed in hospital or 
emergency room (56% vs 74%, P<0.001). 
Distribution of symptoms by type 
Among newly diagnosed atrial fibrillation patients presenting with symptoms, palpitation was 
the most common, accounting for 51.7% symptoms, followed by shortness of breath (41.6%) 
and chest pain/discomfort (25.9%) (patients may have complained of more than 1 symptom). 
Other documented symptoms included tiredness (18.9%), dizziness (16.0%), sweating 
(5.6%), and fainting (5.3%),  
Treatment pattern 
Approaches for stroke prophylaxis in asymptomatic and symptomatic atrial fibrillation 
patients, stratified by baseline CHA2DS2-VASc score <2 and ≥2, are portrayed in Figure 2a 
and 2b, respectively. A slightly larger proportion of asymptomatic patients received OACs ± 
antiplatelets (AP) compared to symptomatic patients (P<0.001). In the lower-risk group 
         
(CHA2DS2-VASc <2), 58.5% of asymptomatic and 52.2% of symptomatic patients received 
OAC drugs; in the higher-risk group (CHA2DS2-VASc ≥2), 71.4% of asymptomatic and 
68.5% of symptomatic patients received oral anticoagulation. Asymptomatic patients were 
less likely to receive AP therapy alone in comparison to symptomatic patients in both the low 
risk (20.6% vs 24.4%, respectively) and high risk (17.5% vs. 21.6%, respectively) categories. 
Patients who were not initiated on anticoagulation were comparable between the two groups.  
Clinical outcomes over 2-years 
Two-year incidence event rates for all-cause mortality, non-hemorrhagic stroke or systemic 
embolism, and major bleeding in asymptomatic and symptomatic atrial fibrillation and 
corresponding HRs (95% CIs) are shown in Figure 3. Unadjusted and adjusted HRs revealed 
no significant differences in the rates of the three outcomes in asymptomatic versus 
symptomatic atrial fibrillation patients.  
Results of comparative effectiveness analyses of OAC (VKA or DOAC) versus no OAC for 
all-cause mortality, non-hemorrhagic stroke/systemic embolism and, major bleeding in 
asymptomatic and symptomatic atrial fibrillation patients are shown in Figure 4a–c. No 
difference was discernible in atrial fibrillation symptoms (present or absent) on effectiveness 
of these medications over time. Significant risk reductions in stroke/systemic embolism with 
OAC use were demonstrated in both groups (asymptomatic: HR, 0.59; 95% CI, 0.43–0.82; 
symptomatic: HR, 0.78; 95% CI, 0.65–0.93), as well as in all-cause mortality (asymptomatic: 
HR, 0.69; 95% CI, 0.59-0.81; symptomatic: HR, 0.77; 95% CI, 0.71-0.85). Both 
demonstrated an increased risk for major bleeding with OAC use (HR, 1.20; 95% CI, 0.85–
1.68 and HR, 1.54; 95% CI, 1.24–1.90, respectively), although it only reached statistical 
significance in the symptomatic patients. 
D 
  
         
ISCUSSION 
Comparing 13,235 asymptomatic and 38,797 symptomatic GARFIELD-AF-registered 
patients over a long-term duration of 2-years, few differences were observed among 
outcomes experienced or treatment received over time. There was no significant difference in 
stroke rates or mortality over 2-years between asymptomatic and symptomatic presentations 
of atrial fibrillation, nor in bleeding rates experienced. Given the likely similarity between 
asymptomatic patients with incidental atrial fibrillation clinical presentations, and those 
detected by opportunistic screening, our findings suggest that opportunistic atrial fibrillation 
screening programs might be worthwhile.  An additional reason to justify screening is that 
asymptomatic atrial fibrillation presentations seem to respond similarly to OAC therapy as 
symptomatic atrial fibrillation. 
Approximately half of asymptomatic and symptomatic patients with CHA2DS2-VASc score 
<2 and two-thirds of those with CHA2DS2-VASc score ≥2 received OAC drugs, with a 
slightly higher treatment rate in asymptomatic than symptomatic patients, irrespective of 
stroke risk category. An important finding was that asymptomatic and symptomatic subsets 
of patients responded equally well to OAC drugs in respect of reduction in ischemic stroke or 
systemic embolism, and with similar increased risk of major bleeding observed on these 
agents in both symptom groups. Unfortunately, large numbers of at-risk asymptomatic and 
symptomatic patients received no treatment, or AP only, despite the relative inefficacy of AP 
in preventing atrial fibrillation-related stroke – as has been observed by others 
35,36
.  
Among GARFIELD-AF patients, one quarter were asymptomatic and three quarters had 
atrial fibrillation symptoms. Almost identical results were reported by the PREFER in atrial 
fibrillation 
21
 and ORBIT-AF 
37
 registries. The European Society of Cardiology (ESC)’s Euro 
Heart Survey on Atrial Fibrillation 
38
 also showed that approximately one-third of atrial 
fibrillation patients were asymptomatic and two-thirds were symptomatic on survey entry.  
         
There were few clinical differences between asymptomatic and symptomatic patients, apart 
from the former being more likely to be male and to have had prior stroke, and the latter to 
have a greater burden of heart failure. Similar observations on the predominance of male sex 
have been consistently reported in other series 
6,21,38-40
.  One possible but unquantifiable 
difference between the groups is the duration of atrial fibrillation prior to enrollment. Patients 
with symptomatic atrial fibrillation may have presented with atrial fibrillation of shorter 
duration compared to those with asymptomatic atrial fibrillation, however both groups had 
atrial fibrillation first diagnosed within 6 weeks of enrollment. In a recent patient-level meta-
analysis of single time-point screening for unknown atrial fibrillation in over 140,000 
individuals, males predominated over females in all age strata 
19
 and in the AFFIRM study 
male sex accounted for 77% of asymptomatic patients 
6
.  AFFIRM also found that 
asymptomatic patients were more likely to have had prior stroke and were less likely to have 
coronary artery disease and heart failure. The finding of higher rates of prior stroke in 
asymptomatic patients is possibly explained by a greater burden of untreated atrial 
fibrillation, as those with symptoms may be more likely to present and receive earlier OAC. 
Symptomatic patients in our study were also significantly more likely to report smoking 
habits and pulmonary disease than asymptomatic counterparts.  
Implementing screening programs in primary care has been suggested 
41
. Numerous attempts 
have been made to discover optimal methods for detecting silent atrial fibrillation in the 
community 
42
; these screening techniques may be described as systematic (mass invitation 
sent to target population, e.g. elderly individuals with risk factors) 
23,43-45
 or opportunistic 
(testing in patients attending a physician visit for any reason) 
13,46-48
. Additionally, in patients 
with symptoms consistent with paroxysmal atrial fibrillation, a clinically-indicated search for 
atrial fibrillation may be advised using similar techniques and technologies. Nearly all 
screening efforts to date have aimed to bypass time-consuming conventional 12-lead 
         
electrocardiogram (ECG) recordings with easier diagnostic methods using ECG handheld 
devices, from wearable recorders to invasively implanted loop recorders 
49
. The advisability 
of ECG screening for atrial fibrillation was recently considered in a systematic literature 
review conducted by the US Preventive Services Task Force 
50,51
. This study concluded that 
screening using either ECG or pulse palpation identified higher numbers of asymptomatic 
adults with newly discovered atrial fibrillation than did no screening, however, there was 
insufficient information to recommend for or against ECG screening. 
In the present study, patients were not identified by mass screening. Therefore, asymptomatic 
cases were likely captured incidentally whereas symptomatic individuals were likely 
diagnosed when seeking treatment for symptoms consistent with atrial fibrillation. This 
would explain why many more asymptomatic cases than symptomatic cases presented in the 
office, rather than in hospital or Emergency Room. Our main findings that asymptomatic and 
symptomatic patients fared equivalently in terms of major adverse outcomes, and response to 
OAC therapy, supports guideline and consensus recommendation for conducting 




This prospective registry study has limitations. Patients were dichotomized into 
asymptomatic and symptomatic groups on the basis of complaints typical of atrial fibrillation 
at baseline. Symptom resolution or subsequent development of new or intermittent symptoms 
may have occurred, but was not recorded over time, however we were primarily interested in 
the prognosis according to symptomatic status at diagnosis. Patients recorded as 
asymptomatic within GARFIELD-AF presented within 6 weeks of entry into the registry and 
thus symptomatic status is recorded somewhat later than patients who are detected by an 
opportunistic screening program.  Whereas follow-up was conducted over 2-years, a 
relatively short time-frame for patients with a lifelong cardiac condition like atrial fibrillation, 
         
this is mitigated by the first year after diagnosis having the highest risk in patients with atrial 
fibrillation 
53-55
. We also have complete and verifiable data collected in a very large group of 
patients, which increases the robustness of the findings. Although we adjusted for all 
covariates available when comparing outcomes between those with and without symptoms, 
and responses to OAC vs no OAC prescription, it is possible that residual confounding 
factors may be present. 
CONCLUSION 
In this analysis of the large, global GARFIELD-AF registry 2-year clinical outcomes did not 
differ, and prescription of antithrombotic therapies was similar among asymptomatic and 
symptomatic atrial fibrillation patients at presentation. Our study also showed that 
asymptomatic patients had a similar response to OAC therapy as symptomatic individuals. As 
patients who are asymptomatic at clinical presentation likely have incidentally-detected atrial 
fibrillation, their prognosis and response to OAC therapy could be expected to mirror that of 
opportunistic screening-detected asymptomatic atrial fibrillation. These findings therefore 
support a likely benefit of screening across populations at risk for "silent atrial fibrillation." 
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Figures 
Title: Clinical outcomes in asymptomatic and symptomatic atrial fibrillation patients in 
GARFIELD-AF: Implications for atrial fibrillation screening 
 Figure 1. Flowchart for selection of study population. 
1
Palpitations, shortness of breath, chest pain/discomfort, dizziness, tiredness, sweating, fainting, other. 
         
Figure 2. Antithrombotic therapy at inclusion following diagnosis in asymptomatic and 
symptomatic atrial fibrillation patients stratified by CHA2DS2-VASc score a) <2 or b) 
≥2. AP, antiplatelet; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K 
antagonist. 
         
Figure 3. Hazard ratios (unadjusted and adjusted
1
) and corresponding 95% CIs for 2-
year outcomes in patients with versus without (reference) symptoms at diagnosis. HR >1 
indicated increased risk for symptomatic patients. 1Adjusted for sex, age, diabetes, hypertension, 
congestive heart failure, vascular disease, prior stroke/transient ischaemic attack/systemic embolism, 
ethnicity, history of bleeding, moderate–severe chronic kidney disease, OAC treatment, smoking 
status, and alcohol consumption. 
2
Combining ischemic and unknown stroke.




 cumulative incidence rates for a) all-cause mortality, b) non-
hemorrhagic stroke/systemic embolism, and c) major bleeding in patients with 
asymptomatic (left curves) and symptomatic (right curves) atrial fibrillation treated 
with OAC or no OAC over 2 years. 1Adjusted for sex, age, diabetes, hypertension, congestive 
heart failure, vascular disease, prior stroke/transient ischaemic attack/systemic embolism, ethnicity, 
history of bleeding, moderate–severe chronic kidney disease, type of atrial fibrillation, OAC 
treatment, smoking status, and alcohol consumption. 
  
         
Tables 
Title: Clinical outcomes in asymptomatic and symptomatic atrial fibrillation patients in 
GARFIELD-AF: Implications for atrial fibrillation screening 
Table 1. Baseline characteristics in asymptomatic and symptomatic patients with atrial 
fibrillation 
Parameter Asymptomatic 
(N = 13,235) 
Symptomatic 
(N = 38,797) 
Sex male, n (%) 8501 (64.2) 20,541 (52.9) 
Age, median (IQR), years 72.0 (65.0–79.0) 70.0 (62.0–78.0) 
Ethnicity, n (%)   
     White 8176 (63.7) 23,829 (62.8) 
     Hispanic/Latino 603 (4.7) 2789 (7.4) 
     Asian 3866 (30.1) 10,416 (27.5) 
     Other 186 (1.4) 883 (2.3) 
BMI, median (IQR), kg/m
2
 26.6 (23.8–30.1) 27.0 (24.0–30.9) 
SBP, median (IQR), mmHg 131.0 (120.0–144.0) 130.0 (120.0–145.0) 
DBP, median (IQR), mmHg 80.0 (70.0–86.0) 80.0 (70.0–90.0) 
Pulse rate, median (IQR), min
–1
 80.0 (70.0–95.0) 86.0 (72.0–110.0) 
Type of atrial fibrillation, n (%)   
     Permanent 2176 (16.4) 4454 (11.5) 
     Persistent 2087 (15.8) 5671 (14.6) 
     Paroxysmal 3324 (25.1) 10,983 (28.3) 
     New onset (unclassified) 5643 (42.7) 17,688 (45.6) 
Care setting location at diagnosis, n (%)   
         
     Hospital 6748 (51.0) 23,593 (60.8) 
     Office 5740 (43.4) 9841 (25.4) 
     AC clinic 102 (0.8) 237 (0.6) 
     Emergency room 639 (4.8) 5125 (13.2) 
Medical history, n (%)   
     Heart failure 1786 (13.5) 9953 (25.7) 
     Acute coronary syndrome 1219 (9.2) 4317 (11.2) 
     Vascular disease
1
 2732 (20.8) 10,086 (26.2) 
     Prior stroke 1438 (10.9) 2440 (6.3) 
     Prior bleeding 372 (2.8) 944 (2.4) 
     Hypertension 9975 (75.6) 29,635 (76.6) 
     Hypercholesterolemia 5241 (40.6) 15,718 (41.9) 
     Diabetes 3037 (23.0) 8509 (21.9) 
     Moderate–severe chronic kidney disease 1411 (11.0) 3944 (10.5) 
Treatment, n (%)   
     NOAC ± AP 3906 (29.8) 10,217 (26.7) 
     VKA ± AP 5187 (39.6) 14,996 (39.3) 
     AP alone 2350 (17.9) 8411 (22.0) 
     None 1659 (12.7) 4581 (12.0) 
CHA2DS2-VASc score, median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 
HAS-BLED score, median (IQR)
2
 1.0 (1.0–2.0) 1.0 (1.0–2.0) 
1
Peripheral artery disease and/or coronary artery disease. 
2
"Labile INR" not collected at baseline; therefore, maximum score 8 (not 9). 
AP, antiplatelet; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; 
NOAC, non-vitamin K antagonist oral anticoagulant; SBP, systolic blood pressure; VKA, vitamin K 
antagonist. 
         
